electroCore Reports 27% Sales Growth to $32M, Guides 30% 2026 Revenue Rise
electroCore posted record 2025 net sales of $32.0 million, up 27% year-over-year, driven by 25% U.S. prescription growth and 97% general wellness expansion. The company ended 2025 with $11.6 million in cash and marketable securities and projects approximately 30% revenue growth for full-year 2026.
1. Record 2025 Financial Performance
electroCore reported full-year 2025 net sales of $32.0 million, a 27% increase over 2024 driven by 25% U.S. prescription growth and 97% general wellness gains. Gross profit rose by $6.4 million to $27.8 million, lifting gross margin to 87% from 85%.
2. 2026 Revenue Guidance
The company forecasts approximately 30% revenue growth for full-year 2026 compared to 2025 levels, targeting continued expansion across prescription and general wellness channels. This projection follows strong performance in gammaCore™, Quell® Fibromyalgia and Truvaga™ product lines.
3. Organizational Leadership Changes
Chief Executive Officer Dan Goldberger will retire on April 1, 2026, with Joshua Lev assuming interim President and Chief Financial Officer duties and Michael Fox joining as Chief Operating Officer. These changes aim to strengthen operational leadership and support planned growth initiatives.
4. Cash Position and Balance Sheet
Total cash, cash equivalents and marketable securities stood at $11.6 million at December 31, 2025, down from $12.2 million a year earlier. Adjusted EBITDA net loss narrowed slightly to $8.7 million, while GAAP net loss widened to $14.0 million due to increased operating expenses.